STOCKS IN FOCUS (22nd July 2026)

STOCKS IN NEWS

• Maruti Suzuki India: Due to the continuous increase in input costs, the company has decided to increase the prices of its models across the portfolio by up to Rs 30,000. The price hike will come into effect in August 2026.
• Aditya Birla Capital: The company has made an investment of Rs 123.89 crore, on a rights basis, in the equity shares of its associate, Aditya Birla Health Insurance Company. Following this investment, there will be no change in Aditya Birla Capital’s percentage shareholding, and Aditya Birla Health Insurance Company will continue to remain an associate of the company.
• Aurobindo Pharma: The company’s subsidiary, CuraTeQ Biologics, has received approval from ANVISA (Agência Nacional de Vigilância Sanitária), Brazil’s National Health Surveillance Agency, for its biosimilars manufacturing facility in Hyderabad. The facility underwent a Good Manufacturing Practice (GMP) inspection by ANVISA from May 11 to May 15, 2026, and the approval was granted following the successful completion of the inspection for biological APIs and sterile products.
• Ather Energy: The EV maker’s stock will remain in focus after it, successfully raised Rs 1,300 crore through a QIP on Tuesday.
• Mahindra Finance: The company’s share will remain in focus after it reported a 75 per cent jump in Q1 consolidated net profit to Rs 927 crore, driven by higher net interest margins and lower provisions.

BULK DEALS

• Bliss GVS Pharma: Foreign portfolio investor Nova Vida bought 7 lakh shares, representing a 0.66 percent stake, in Bliss GVS Pharma from Arian Investment. The shares of the pharma company changed hands at Rs 485 per share, valuing the deal at Rs 33.95 crore. According to the shareholding pattern as of March 2026, Arian Investment held a 2.45 percent stake (25.93 lakh shares) in Bliss GVS Pharma.
• . Manba Finance: Ved Investments acquired 3.55 lakh shares, representing a 0.7 percent stake, in Manba Finance at Rs 138 per share, valuing the deal at Rs 4.9 crore.

Source: Moneycontrol, Business Standard

Disclaimer:

Investment in securities markets is subject to market risks. Please read all related documents carefully before investing. (Our SEBI Reg. No. INH000010335)

For Full Disclaimer: Click Here